{"id":43962,"date":"2022-05-16T23:01:15","date_gmt":"2022-05-16T21:01:15","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\/"},"modified":"2022-05-16T23:01:15","modified_gmt":"2022-05-16T21:01:15","slug":"veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\/","title":{"rendered":"Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test\u2019s Clinical Performance and Utility in Lung Cancer Risk Assessment"},"content":{"rendered":"
\n

\nFindings Presented at ATS 2022<\/i>\n<\/p>\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc.<\/a> (Nasdaq: VCYT) today announced new data showing that its Percepta Nasal Swab test accurately assesses lung cancer risk among current and former smokers with lung nodules, regardless of their smoking history burden and whether they are considered high risk for lung cancer based on U.S. Preventive Services Task Force (USPSTF) screening criteria. The findings were presented today at the American Thoracic Society 2022 International Conference (ATS 2022), being held in San Francisco.\n<\/p>\n

<\/a><\/p>\n

\n\u201cOur analysis showed that the nasal genomic classifier performed similarly well in patients across the spectrum of tobacco-related risk,” said Carla R. Lamb, M.D., a pulmonary and critical care physician and Director of Interventional Pulmonary at Lahey Hospital & Medical Center who presented the study findings. \u201cThese findings suggest that the test can be reliably used in ever-smokers whose lung nodules were found incidentally, as well as through screening.\u201d\n<\/p>\n

\nFor the study, researchers evaluated data from a subset of 291 current and former smokers with lung nodules who were part of the original clinical validation study for the Percepta Nasal Swab test. Among these individuals, 213 (73%) met USPSTF screening criteria (pack years \u226520, years since quit <15, age 50-80 years), while 78 (27%) did not. Researchers compared the performance of the classifier in the two patient subsets and found no statistically significant differences in the classifier\u2019s sensitivity and specificity between the two groups.\n<\/p>\n

\nSpecifically, among those who met the USPSTF criteria for lung cancer screening, the test\u2019s sensitivity was 96% when it identified a nodule as low risk for cancer and its specificity was 94% when it identified it as high risk. Among patients who did not meet the USPSTF lung cancer screening eligibility, the test\u2019s sensitivity was 100% when it identified nodules as low risk for cancer and its specificity was 88% when it identified them as high risk.\n<\/p>\n

\n\u201cThe data presented today reinforce the important role that the Percepta Nasal Swab classifier may play in helping to guide next steps for current and former smokers with lung nodules \u2013 including those who may be considered low risk based on their smoking history burden,\u201d said Giulia C. Kennedy, Ph.D., Veracyte\u2019s global chief scientific officer and chief medical officer. \u201cMore accurate, timely diagnosis of these patients could ultimately lead to fewer unnecessary diagnostic procedures among those without lung cancer, and timelier treatment for those with the disease.\u201d\n<\/p>\n

\nThe Percepta Nasal Swab test\u2019s performance in classifying lung cancer risk has previously been demonstrated, and it is being made available to a limited number of sites as the company develops the clinical utility evidence to support reimbursement.\n<\/p>\n

\nAlso at ATS 2022, Veracyte will host two Learning Theater events during which leading physicians will discuss their experiences incorporating novel genomic testing into the diagnoses of interstitial lung disease (ILD) and lung cancer, respectively:\n<\/p>\n

\nTitle<\/b>: Integrating novel genomic data to improve ILD diagnostic and prognostic confidence
\n
Presenter<\/b>: Lisa H. Lancaster, M.D.
\n
Date\/Time<\/b>: May 17, 12:30 p.m. PT
\n
Location<\/b>: Mini Theater #2\n<\/p>\n

\nTitle<\/b>: Integrating the Percepta Genomic Sequencing Classifier for lung nodule risk stratification
\n
Presenters<\/b>: David Feller-Kopman, M.D. and Shaheen Islam, M.D.
\n
Date\/Time<\/b>: May 17, 1:30 p.m. PT
\n
Location<\/b>: Mini Theater #1\n<\/p>\n

\nAbout Veracyte<\/b>\n<\/p>\n

\nVeracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and reduce time to appropriate treatment. Our tests address eight of the 10 most prevalent cancers by incidence in the United States. In addition to making our tests available in the United States through our central laboratories, our exclusive license to a best-in-class diagnostics instrument positions us to deliver our tests to patients worldwide through laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com<\/a> and follow the company on Twitter (@veracyte).\n<\/p>\n

\nCautionary Note Regarding Forward-Looking Statements<\/b>\n<\/p>\n

\nThis press release contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to Veracyte\u2019s Percepta Nasal Swab test. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” \u201csuggest,\u201d “may,” “will” \u201cprospective\u201d and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. An example of a forward-looking statement includes, among others, that the Percepta Nasal Swab may help patients more accurately, quickly and confidently assess lung cancer risk so that patients may avoid unnecessary invasive procedures. Additional factors that may impact these forward-looking statements can be found under the caption \u201cRisk Factors\u201d in our Annual Report on Form 10-K filed with the SEC on February 28, 2022, and our subsequent quarterly reports on Form 10-Q. A copy of these documents can be found at the Investors section of our website at www.veracyte.com<\/a>. These forward-looking statements speak only as of the date hereof and, except as required by law, Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.\n<\/p>\n

\nVeracyte, the Veracyte logo, HalioDx, Decipher, Decipher GRID, Afirma, Percepta, Envisia, Prosigna, Lymphmark, \u201cKnow by Design\u201d and \u201cMore about You\u201d are registered trademarks of Veracyte, Inc. and its affiliates in the U.S. and selected countries. nCounter is the registered trademark of NanoString Technologies, Inc. in the U.S. and selected countries and used by Veracyte under license.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors:<\/b>
Shayla Gorman
\n
investors@veracyte.com<\/a>
619-393-1545\n<\/p>\n

\nMedia:<\/b>
Tracy Morris
\n
Vice President of Global Corporate Communications
\n
tracy.morris@veracyte.com<\/a>
650-380-4413\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Findings Presented at ATS 2022 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) today announced new data showing that its Percepta Nasal Swab test accurately assesses lung cancer risk among current and former smokers with lung nodules, regardless of their smoking history burden and whether they are considered high risk for lung cancer based on … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-43962","format-standard","category-industry"],"yoast_head":"\nVeracyte Announces New Data Reinforcing Percepta Nasal Swab Test\u2019s Clinical Performance and Utility in Lung Cancer Risk Assessment - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test\u2019s Clinical Performance and Utility in Lung Cancer Risk Assessment - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Findings Presented at ATS 2022 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) today announced new data showing that its Percepta Nasal Swab test accurately assesses lung cancer risk among current and former smokers with lung nodules, regardless of their smoking history burden and whether they are considered high risk for lung cancer based on ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-16T21:01:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220516006017\/en\/791654\/21\/Veracyte_RGB_LRG_H_registered.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test\u2019s Clinical Performance and Utility in Lung Cancer Risk Assessment\",\"datePublished\":\"2022-05-16T21:01:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\\\/\"},\"wordCount\":963,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220516006017\\\/en\\\/791654\\\/21\\\/Veracyte_RGB_LRG_H_registered.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\\\/\",\"name\":\"Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test\u2019s Clinical Performance and Utility in Lung Cancer Risk Assessment - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220516006017\\\/en\\\/791654\\\/21\\\/Veracyte_RGB_LRG_H_registered.jpg\",\"datePublished\":\"2022-05-16T21:01:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220516006017\\\/en\\\/791654\\\/21\\\/Veracyte_RGB_LRG_H_registered.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220516006017\\\/en\\\/791654\\\/21\\\/Veracyte_RGB_LRG_H_registered.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test\u2019s Clinical Performance and Utility in Lung Cancer Risk Assessment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test\u2019s Clinical Performance and Utility in Lung Cancer Risk Assessment - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\/","og_locale":"en_US","og_type":"article","og_title":"Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test\u2019s Clinical Performance and Utility in Lung Cancer Risk Assessment - Pharma Trend","og_description":"Findings Presented at ATS 2022 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) today announced new data showing that its Percepta Nasal Swab test accurately assesses lung cancer risk among current and former smokers with lung nodules, regardless of their smoking history burden and whether they are considered high risk for lung cancer based on ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-16T21:01:15+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220516006017\/en\/791654\/21\/Veracyte_RGB_LRG_H_registered.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test\u2019s Clinical Performance and Utility in Lung Cancer Risk Assessment","datePublished":"2022-05-16T21:01:15+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\/"},"wordCount":963,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220516006017\/en\/791654\/21\/Veracyte_RGB_LRG_H_registered.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\/","url":"https:\/\/pharma-trend.com\/en\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\/","name":"Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test\u2019s Clinical Performance and Utility in Lung Cancer Risk Assessment - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220516006017\/en\/791654\/21\/Veracyte_RGB_LRG_H_registered.jpg","datePublished":"2022-05-16T21:01:15+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220516006017\/en\/791654\/21\/Veracyte_RGB_LRG_H_registered.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220516006017\/en\/791654\/21\/Veracyte_RGB_LRG_H_registered.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/veracyte-announces-new-data-reinforcing-percepta-nasal-swab-tests-clinical-performance-and-utility-in-lung-cancer-risk-assessment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test\u2019s Clinical Performance and Utility in Lung Cancer Risk Assessment"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/43962","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=43962"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/43962\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=43962"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=43962"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=43962"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}